• Expanded Access Programs
  • Imports (Unlicensed Medicines)
  • International Sales
  • Clinical Trial Supply
  • Sales to NGOs & Charities
  • Sexual Health Supplies
  • Bespoke Distribution
  • Durbin USA
  • About Us
  • News
  • Contact Us
  • News

    Durbin Announces Managed Access Program for Diacerein 1% Ointment for the Treatment of Epidermolysis Bullosa Simplex

    18 April 2018

    - Epidermolysis Bullosa Simplex (EBS) is a rare dermatologic condition affecting one in 30,000 to 50,000 people. -

    - Diacerein 1% ointment (CCP-020) is an investigational drug being developed by Castle Creek Pharmaceuticals, USA. -

    Hayes, UK – April, 2018 – Durbin Group (Durbin), a specialist pharmaceutical supplier distributing pharmaceuticals to 180 different countries with extensive experience in the distribution of medications, today announced that Castle Creek Pharmaceuticals (CCP), a U.S. based global biotech company dedicated to delivering transformative therapies to patients with rare dermatologic and other underserved conditions, has appointed Durbin as the worldwide distributor for a Managed Access Program (MAP) for Diacerein 1% ointment (CCP-020) for the treatment of Epidermolysis Bullosa Simplex (EBS).

    EBS is the most common form of epidermolysis bullosa, a rare hereditary disease where patients, many of them children, have a genetic defect that compromises the structural integrity of their skin, making it particularly fragile and prone to blistering throughout their bodies. The disease can be severely debilitating. Current standard of care is preventative and palliative as there are no medications, products, or procedures that have been shown to effectively treat the underlying causes of EBS. CCP-020 is an investigational topical drug that is currently being evaluated in the Phase 2/3 DELIVERS study for the treatment of EBS.

    “We have been conducting a clinical trial evaluating the safety and efficacy of CCP-020 for the treatment of EBS (ClinicalTrials.gov Identifier: NCT03154333), and the response from physicians has been overwhelmingly positive,” said Amir Tavakkol, PhD, executive vice president and chief development officer of CCP. “However, not all patients meet study requirements to participate in clinical trials. As a result of increasing patient requests, we need an experienced partner with a track record, global reach, international regulatory expertise, and an inclusive partnership approach to provide treatment to those patients. Durbin meets these criteria and we are pleased to be working with them.”

    Under this program, CCP will make CCP-020 available in collaboration with Durbin in response to unsolicited requests by dermatologists and other clinical specialists on an individual named-patient basis in accordance with local and international regulations. Additional details can be obtained from Durbin by contacting CastleCreekAccess@Durbinglobal.com.

    “CCP is an innovative and dynamic company that is striving to develop therapies for patients with a devastating rare skin disease,” said Leslie Morgan, OBE, DL, managing director of Durbin. “We are pleased to be working in partnership with such a progressive company run by an experienced leadership team to help people living with EBS. In our 50 years of trading we have built up a high level of expertise running programs like this, which are about putting patients’ needs first. It is clear CCP shares our dedication to improving patients’ lives.”

    About Durbin

    Durbin is a specialist pharmaceutical supplier distributing pharmaceuticals to 180 different countries. Durbin works in partnership with global Pharmaceutical and Biotech companies providing Managed Access Programs, including Named Patient Supply and Clinical Trial Supply goods.

    About Castle Creek Pharmaceuticals

    Castle Creek Pharmaceuticals (CCP), part of the Paragon Biosciences portfolio of innovative biotech companies, is a privately held biopharmaceutical company developing innovative therapies for patients with rare, serious or debilitating dermatologic conditions. The company has a robust and diversified pipeline of late-stage products that have the potential to transform lives. For more information, please visit www.castlecreekpharma.com.

    Media contacts:


    Robert Donnell
    Head of Business Development
    +44 208 869 6515

    Castle Creek Pharmaceuticals

    Adam Daley
    Berry & Company Public Relations
    +1 212-253-8881

    Press Releases